Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 2206-2208

  Nannini, Esteban C ^a   Stryjewski, Martin E ^b,c   Singh, Kavindra V ^e   Rude, Tom H ^d   Ralph Corey, G ^d   Fowler Jr , Vance G ^d   Murray, Barbara E ^e,f  

^a UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c CEMIC   (Argentina)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Center for the Study of Emerging and Reemerging Pathogens   (United States)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE TYPE A; BETA LACTAMASE TYPE C; CEFALEXIN; CEFALOTIN; CEFTOBIPROLE; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; NAFCILLIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; INOCULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CEFTRIAXONE; CEFUROXIME; CEPHALEXIN; CEPHALOSPORINS; CEPHALOTHIN; HUMANS; METHICILLIN; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 77951235014     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01325-09     Document Type: Article

References (23)

1. Bruns, W., and H. Keppeler. 1987. Extracellular and membrane-bound beta lactamase of Staphylococcus aureus: their importance for the expression of penicillin resistance. J. Med. Microbiol. 23:133-139.
2. Bryant, R. E., and R. H. Alford. 1977. Unsuccessful treatment of staphylococcal endocarditis with cefazolin. JAMA 237:569-570.
3. Clinical and Laboratory Standards Institute. 2008. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th edition. CLSI document M07-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Fernández-Guerrero, M. L., and M. de Gorgolas. 2005. Cefazolin therapy for Staphylococcus aureus bacteremia. Clin. Infect. Dis. 41:127.
5. Francioli, P. B. 1993. Ceftriaxone and outpatient treatment of infective endocarditis. Infect. Dis. Clin. North Am. 7:97-115.
6. Gavaldà, J., P. Lopez, T. Martin, X. Gomis, J. L. Ramirez, C. Azuaje, B. Almirante, and A. Pahissa. 2002. Efficacy of ceftriaxone and gentamicin given once a day by using human-like pharmacokinetics in treatment of experimental staphylococcal endocarditis. Antimicrob. Agents Chemother. 46:378-384.
7. Goldman, P. L., and R. G. Petersdorf. 1980. Importance of beta-lactamase inactivation in treatment of experimental endocarditis caused by Staphylococcus aureus. J. Infect. Dis. 141:331-337.
8. Guglielmo, B. J., A. D. Luber, D. Paletta, Jr., and R. A. Jacobs. 2000. Ceftriaxone therapy for staphylococcal osteomyelitis: a review. Clin. Infect. Dis. 30:205-207.
9. Kernodle, D. S., P. A. McGraw, C. W. Stratton, and A. B. Kaiser. 1990. Use of extracts versus whole-cell bacterial suspensions in the identification of Staphylococcus aureus β-lactamase variants. Antimicrob. Agents Chemother. 34:420-425.
10. Laverdiere, M., D. Welter, and L. D. Sabath. 1978. Use of a heavy inoculum in the in vitro evaluation of the anti-staphylococcal activity of 19 cephalosporins. Antimicrob. Agents Chemother. 13:669-675.
11. Miro, J. M., I. Anguera, C. H. Cabell, A. Y. Chen, J. A. Stafford, G. R. Corey, L. Olaison, S. Eykyn, B. Hoen, E. Abrutyn, D. Raoult, A. Bayer, and V. G. Fowler, Jr. 2005. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin. Infect. Dis. 41:507-514.
12. Nannini, E. C., K. V. Singh, and B. E. Murray. 2003. Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. Clin. Infect. Dis. 37:1194-1198.
13. Nannini, E. C., M. E. Stryjewski, K. V. Singh, A. Bourgogne, T. H. Rude, G. R. Corey, V. G. Fowler, Jr., and B. E. Murray. 2009. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob. Agents Chemother. 53:3437-3441.
14. Queenan, A. M., W. Shang, M. Kania, M. G. Page, and K. Bush. 2007. Interactions of ceftobiprole with β-lactamases from molecular classes A to D. Antimicrob. Agents Chemother. 51:3089-3095.
15. Quinn, E. L., D. Pohlod, T. Madhavan, K. Burch, E. Fisher, and F. Cox. 1973. Clinical experiences with cefazolin and other cephalosporins in bacterial endocarditis. J. Infect. Dis. 128(Suppl.):S386-S389.
16. Rosdahl, V. T. 1986. Penicillinase production in Staphylococcus aureus strains of clinical importance. Dan. Med. Bull. 33:175-184.
17. Sabath, L. D., C. Garner, C. Wilcox, and M. Finland. 1975. Effect of inoculum and of beta-lactamase on the anti-staphylococcal activity of thirteen penicillins and cephalosporins. Antimicrob. Agents Chemother. 8:344-349.
18. Skov, R., N. Frimodt-Moller, and F. Espersen. 2002. In vitro susceptibility of Staphylococcus aureus towards amoxycillin-clavulanic acid, penicillin-clavulanic acid, dicloxacillin and cefuroxime. APMIS 110:559-564.
19. Steckelberg, J. M., M. S. Rouse, B. M. Tallan, D. R. Osmon, N. K. Henry, and W. R. Wilson. 1993. Relative efficacies of broad-spectrum cephalosporins for treatment of methicillin-susceptible Staphylococcus aureus experimental infective endocarditis. Antimicrob. Agents Chemother. 37:554-558.
20. Tallan, B. M., M. S. Rouse, D. S. Kernodle, J. M. Steckelberg, N. K. Henry, and W. R. Wilson. 1991. Effect of quantity and location of Staphylococcus aureus beta-lactamase on outcome of cephalosporin treatment of experimental endocarditis. Abstr. 31st Intersci. Conf. Antimicrob. Agents Chemother., abstr. 363.
21. Voladri, R., M. Tummuru, and D. Kernodle. 1996. Structure-function relationships among wild-type variants of Staphylococcus aureus β-lactamase: importance of amino acids 128 and 216. J. Bacteriol. 178:7248-7253.
22. Voladri, R. K., and D. S. Kernodle. 1998. Characterization of a chromosomal gene encoding type B β-lactamase in phage group II isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 42:3163-3168.
23. Zygmunt, D. J., C. W. Stratton, and D. S. Kernodle. 1992. Characterization of four β-lactamases produced by Staphylococcus aureus. Antimicrob. Agents Chemother. 36:440-445.